Pharmacological Targeting of MTHFD2 Suppresses NSCLC Via the Regulation of ILK Signaling Pathway
Feng Zhou,Ziyi Yuan,Yuyan Gong,Luyao Li,Yanmao Wang,Xian Wang,Chunbo Ma,Lehe Yang,Zhiguo Liu,Liangxing Wang,Haiyang Zhao,Chengguang Zhao,Xiaoying Huang
DOI: https://doi.org/10.1016/j.biopha.2023.114412
IF: 7.419
2023-01-01
Biomedicine & Pharmacotherapy
Abstract:Lung cancer is the most common cause of cancer related deaths worldwide with the highest mortality rate. Nonsmall cell lung cancer (NSCLC) accounts for about 85 % of lung cancers. Mitochondrial methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) is a bifunctional enzyme and is the most differentially expressed metabolic enzyme in various tumors including lung cancer. However, little is known about how MTHFD2 functions in NSCLC. Integrin-linked kinase (ILK) signaling plays key a role in tumor progression including metastasis, proliferation and migration. Here, we show that MTHFD2 inhibition results in suppression of cell growth, migration, invasion and epithelial-mesenchymal transition (EMT) in NSCLC. Microarray analysis suggests that MTHFD2 is positively associated with ILK signaling based on western blotting results. In addition, the phosphorylation of AMPK alpha plays an essential role in MTHFD2 regulation of ILK signaling. Further, the small-molecule compound C18 inhibits MTHFD2 with great efficiency. C18 blocks MTHFD2/ILK signaling pathway and restrains cell growth, migration, invasion, and EMT of NSCLC and induces apoptosis. In brief, our study found that the positive impact of MTHFD2 is mediated via ILK signaling pathway in NSCLC. Thus, blocking MTHFD2 represents a promising therapeutic strategy against NSCLC clinically.